Convalescent plasma from Norwegian blood donors to treat COVID-19.

Background: At the start of the pandemic, the Norwegian Directorate of Health and Norwegian blood banks initiated the production of COVID-19 convalescent plasma within the framework of clinical studies. In this article we describe the blood donors who participated.

Material And Method: Blood donors who had recovered from COVID-19 were recruited to donate single donor plasma for the purpose of patient treatment.

COVID-19 patients treated with convalescent plasma.

Background: In Norway, treatment with COVID-19 convalescent plasma has been given through the NORPLASMA project. The treatment was initially offered to critically ill patients after an individual assessment, but from December 2020, the indication was limited to critically ill, immunocompromised patients. In this article we describe clinical characteristics, comorbidity and mortality in patients who received convalescent plasma in these two periods.

[Transfusion practice at Sørlandet Hospital].

Background: Norway has no overview of the number of patients who are transfused, their age and gender distribution or reasons for transfusion. We wished to investigate which patient groups received blood at Sørlandet Hospital in 2010-2011, and to test a method of electronic data linkage from treatment systems, with a view to further monitoring of blood consumption.

Material And Method: Data from all patients treated in somatic departments at Sørlandet Hospital in the period from 1 January 2010 to 31 December 2011 were linked to data from the blood bank with the aid of the system 'Forskning i sykehus'.